|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net of allowances of $0 and $0 at June 30, 2020 and December 31, 2019, respectively | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net of accumulated depreciation and amortization of $9,955 and $7,925 at June 30, 2020 and December 31, 2019, respectively | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Deferred revenues | ||||||||||||||||||||
| Liability related to sale of future royalties - current | ||||||||||||||||||||
| Lease liability - current | ||||||||||||||||||||
| Convertible senior notes, net | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible senior notes, net | ||||||||||||||||||||
| Non-recourse debt | ||||||||||||||||||||
| Accrued interest expense on non-recourse debt | ||||||||||||||||||||
| Liability related to sale of future royalties - non-current | ||||||||||||||||||||
| Deferred revenues | ||||||||||||||||||||
| Lease liability - non-current | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Commitments and Contingencies (Note 12) | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2020 and December 31, 2019 | ||||||||||||||||||||
| Common stock, $0.01 par value; authorized 275,000,000 shares at June 30, 2020 (250,000,000 at December 31, 2019); issued 231,073,471 shares and outstanding 230,953,850 shares at June 30, 2020; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019 | ||||||||||||||||||||
| Capital contributed in excess of par | ||||||||||||||||||||
| Treasury stock, at cost: 119,621 shares at June 30, 2020 and December 31, 2019 | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Immunomedics, Inc. stockholders' equity | ||||||||||||||||||||
| Noncontrolling interest in subsidiary | ||||||||||||||||||||
| Convertible preferred stock | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
